The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

EU asks AstraZeneca to publish vaccine contract after CEO's disclosures -source

Wed, 27th Jan 2021 10:07

BRUSSELS, Jan 27 (Reuters) - The European Union is asking
AstraZeneca to publish the contract it signed with the
bloc on COVID-19 vaccine supplies after the company's chief
executive revealed confidential clauses, an EU official said on
Wednesday.

In an interview with newspapers on Tuesday, AstraZeneca CEO
Pascal Soriot said the EU contract was based on a best-effort
clause and did not commit the company to a specific timetable
for deliveries.

The interview followed the company's announcement of a cut
in supplies to the EU in the first quarter.

The EU official said on Wednesday that the best-effort
clause was standard in contracts with manufacturers of products
that are in development.
(Reporting by Francesco Guarascio; editing by Jason Neely
@fraguarascio)

Related Shares

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...

2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.